TickerGuard
Buy Day today: Good (62) Broad market participation · no major macro event
CELU

Celularity Inc

Healthcare · Biotechnology

1.30$ -1.6% vs. previous close Closing price · As of: Sep 17, 2026

Ownership

Ownership Structure

Who owns Celularity Inc (CELU)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 65.2% of the shares are freely tradable; institutional investors hold 12.8%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 12.8%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 37.2%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 65.2%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 28.5%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 29Mio.

Largest Shareholders

Institutions

Institutions CELU
Name Stake (%) Shares Change (%) Date
C V Starr & Co Inc 2.64 764,069 +0.0 06/30/2026
Vanguard Capital Management, LLC 2.15 621,105 +0.0 03/31/2026
Geode Capital Management, LLC 0.66 191,076 +19.3 03/31/2026
BlackRock Inc 0.44 127,501 +11.0 03/31/2026
Citadel Advisors Llc 0.34 99,054 +0.0 06/30/2026
Vanguard Fiduciary Trust Co 0.28 79,874 +0.0 03/31/2026
State Street Corp 0.20 57,830 +0.0 03/31/2026

Funds

Funds CELU
Name Stake (%) Shares Change (%) Date
Vanguard MStar Total Stk Mkt Idx Invest 1.57 455,049 +0.0 07/31/2026
Vanguard Institutional Extnd Mkt Idx Tr 0.57 166,056 +0.0 07/31/2026
Fidelity Extended Market Index 0.30 87,423 -0.2 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?